血糖モニタリング装置の世界市場：将来予測

当レポートでは、世界の血糖モニタリング装置 - 持続血糖モニタリング装置 (CGMS) および自己血糖測定装置 (SMBG) - の市場の将来展望について分析し、製品の特性や市場の基本構造、主な促進・抑制要因、市場全体およびコンポーネント別・エンドユーザー別・用途別・年齢層別・地域別の市場動向見通し (今後9年間分)、主要企業のプロファイルなどを調査しております。

第1章 分析範囲

第2章 分析手法

第3章 エグゼクティブ・サマリー

第4章 市場のダイナミクス

• 市場の定義と範囲
• 市場促進要因
• 市場抑制要因
• 市場機会
• 市場の課題

第5章 持続血糖モニタリング装置 (CGMS) 市場：コンポーネントの種類別

• センサー
• 受信器・送信器
• インスリンポンプ

第6章 CGMS市場：エンドユーザー別

• 在宅治療
• 診断センター・診療所
• 病院

第7章 CGMS市場：年齢層別

• 成人向け (14歳以上)
• 子供向け (14歳以下)

第8章 自己血糖測定装置 (SMBG) 市場の概要

第9章 SMBG市場：コンポーネントの種類別

• 試験紙
• 血糖値計
• ランセット

第10章 SMBG市場：エンドユーザー別

• 在宅治療
• 診療所 (クリニック)
• 病院

第11章 SMBG市場：用途別

• 1型糖尿病
• 2型糖尿病
• 妊娠糖尿病

第12章 主な分析指標

• ポーターのファイブフォース分析
• 主な購入基準
• 主要動向
  • 高品質のウェアラブル機器の開発
  • モバイル医療に対応した、医療機器の使い勝手の向上
  • 認知度上昇に向けた取り組みの強化
  • 非侵襲デバイスの増加
  • エネルギーハーベスト (環境発電) 技術：連続使用向け
• 血糖値の規制
• バリューチェーン分析
• 市場機会マトリックス

第13章 地域別分析

• 北米 (米国、カナダ)
  • 各国の医療提供体制
  • 各国の医薬品市場／医療市場／糖尿病市場
• 欧州 (英国、フランス、ドイツ、イタリア、スペイン、ロシアなど)
• アジア太平洋地域 (中国、インド、オーストラリア、日本、韓国、インドネシア、マレーシア、フィリピン、タイ、ベトナムなど)
• 他の国々 (RoW：ラテンアメリカ (ブラジル、メキシコ)、中東・アフリカ)

第14章 競争環境

• 市場ポジショニング分析
• 企業プロファイル
  • ABBOTT
  • APEX BIOTECHNOLOGY CORP.
  • ARKRAY INC.
  • ASCENSIA
  • B BRAUN MELSUNGEN AG
  • BECTON DICKINSON AND COMPANY
  • DEXCOM
  • GLYSENS INC.
  • INSULET CORP.
  • I-SENS INC.
  • JOHNSON AND JOHNSON
  • MEDTRONIC
  • MOREPEN LABORATORIES LTD.
  • NEMAURA MEDICAL INC.
  • ROCHE DIAGNOSTICS
  • SENSEONICS INC.
  • TANDEM DIABETES CARE
  • テルモ
  • WOCKHARDT
  • YPSOMED

LIST OF TABLES

• TABLE 1 GLOBAL CGMS MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 2 GLOBAL SMBG MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 3 DIABETES PREVALENCE IN VARIOUS GEOGRAPHIES 2015-2040 (MILLIONS)
• TABLE 4 GLOBAL CGMS MARKET BY COMPONENT TYPE 2019-2027 ($ MILLION)
• TABLE 5 GLOBAL CGMS SENSORS MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 6 GLOBAL CGMS TRANSMITTERS AND RECEIVERS MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 7 GLOBAL CGMS INSULIN PUMP MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 8 GLOBAL CGMS MARKET BY END-USER 2019-2027 ($ MILLION)
• TABLE 9 GLOBAL CGMS HOME SETTINGS MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 10 GLOBAL CGMS DIAGNOSTICS AND CLINICAL MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 11 GLOBAL CGMS HOSPITAL MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 12 GLOBAL CGMS MARKET BY DEMOGRAPHICS 2019-2027 ($ MILLION)
• TABLE 13 GLOBAL CGMS ADULT POPULATION (>14YEARS) MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 14 GLOBAL CGMS CHILD POPULATION (≤14YEARS) MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 15 IMPORTANT ASPECTS FOR THE USE OF SMBG DEVICES IN HOME-CARE SETTINGS
• TABLE 16 SMBG STRIPS USAGE SCENARIO IN SELECTED COUNTRIES IN AMERICAS
• TABLE 17 PRODUCT MATRIX FOR LANCETS
• TABLE 18 GLOBAL SMBG MARKET BY COMPONENT TYPE 2019-2027 ($ MILLION)
• TABLE 19 GLOBAL SMBG LANCETS MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 20 GLOBAL SMBG MARKET BY END-USER 2019-2027 ($ MILLION)
• TABLE 21 GLOBAL SMBG HOME SETTING MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 22 GLOBAL SMBG CLINICAL MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 23 GLOBAL SMBG HOSPITAL MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 24 GLOBAL SMBG MARKET BY APPLICATION 2019-2027 ($ MILLION)
• TABLE 25 GLOBAL SMBG TYPE 1 DIABETES MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 26 GLOBAL SMBG TYPE 2 DIABETES MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 27 GLOBAL SMBG GESTATIONAL DIABETES MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 28 GLOBAL SMBG MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 29 GLOBAL CGMS MARKET BY REGION 2019-2027 ($ MILLION)
• TABLE 30 CONVERSION RATE USED FOR DIFFERENT CURRENCIES INTO DOLLAR
• TABLE 31 NORTH AMERICA SMBG MARKET 2019-2027 ($ MILLION)
• TABLE 32 NORTH AMERICA CGMS MARKET 2019-2027 ($ MILLION)
• TABLE 33 EUROPE SMBG MARKET 2019-2027 ($ MILLION)
• TABLE 34 EUROPE CGMS MARKET 2019-2027 ($ MILLION)
• TABLE 35 AVERAGE PRICES IN UK FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER
• TABLE 36 THE UNITED KINGDOM SMBG SALES CHANNEL 2019-2027 ($ MILLION)
• TABLE 37 AVERAGE PRICES IN GERMANY FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER
• TABLE 38 GERMANY SMBG SALES CHANNEL 2019-2027 ($ MILLION)
• TABLE 39 ASIA-PACIFIC SMBG MARKET 2019-2027 ($ MILLION)
• TABLE 40 AVERAGE PRICES IN CHINA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER
• TABLE 41 CHINA SMBG SALES CHANNEL 2019-2027 ($ MILLION)
• TABLE 42 AVERAGE PRICES IN INDIA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
• TABLE 43 INDIA SMBG SALES CHANNEL 2019-2027 ($ MILLION)
• TABLE 44 AVERAGE PRICES IN AUSTRALIA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
• TABLE 45 AUSTRALIA SMBG SALES CHANNEL 2019-2027 ($ MILLION)
• TABLE 46 AVERAGE PRICES IN JAPAN FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
• TABLE 47 JAPAN SALES CHANNEL 2019-2027 ($ MILLION)
• TABLE 48 AVERAGE PRICES IN SOUTH KOREA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
• TABLE 49 SOUTH KOREA SMBG SALES CHANNEL 2019-2027 ($ MILLION)
• TABLE 50 AVERAGE PRICES IN INDONESIA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
• TABLE 51 INDONESIA SMBG SALES CHANNEL 2019-2027 ($ MILLION)
• TABLE 52 AVERAGE PRICES IN MALAYSIA FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
• TABLE 53 MALAYSIA SMBG SALES CHANNEL 2019-2027 ($ MILLION)
• TABLE 54 AVERAGE PRICES IN PHILIPPINES FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
• TABLE 55 PHILIPPINES SMBG SALES CHANNEL 2019-2027 ($ MILLION)
• TABLE 56 AVERAGE PRICES IN THAILAND FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
• TABLE 57 THAILAND SMBG SALES CHANNEL 2019-2027 ($ MILLION)
• TABLE 58 AVERAGE PRICES IN VIETNAM FOR GLUCOSE TEST STRIPS, LANCETS AND GLUCOSE METER (US $)
• TABLE 59 VIETNAM SMBG SALES CHANNEL 2019-2027 ($ MILLION)
• TABLE 60 REST OF WORLD SMBG MARKET 2019-2027 ($ MILLION)
• TABLE 61 REST OF WORLD CGMS MARKET 2019-2027 ($ MILLION)
• TABLE 62 SMBG COMPANY MARKET POSITION ANALYSIS 2018
• TABLE 63 CGMS COMPANY MARKET POSITION ANALYSIS 2018

LIST OF FIGURES

• FIGURE 1 GLOBAL CGMS MARKET SHARE BY COMPONENT TYPE 2018 & 2027 (%)
• FIGURE 2 GLOBAL CGMS MARKET BY SENSORS 2019-2027 ($ MILLION)
• FIGURE 3 GLOBAL CGMS MARKET BY TRANSMITTERS AND RECEIVERS 2019-2027 ($ MILLION)
• FIGURE 4 GLOBAL CGMS MARKET BY INSULIN PUMP 2019-2027 ($ MILLION)
• FIGURE 5 GLOBAL CGMS SHARE BY END-USER 2018 & 2027 (%)
• FIGURE 6 GLOBAL CGMS MARKET BY HOME SETTING 2019-2027 ($ MILLION)
• FIGURE 7 GLOBAL CGMS MARKET BY DIAGNOSTICS AND CLINICAL 2019-2027 ($ MILLION)
• FIGURE 8 GLOBAL CGMS MARKET BY HOSPITAL 2019-2027 ($ MILLION)
• FIGURE 9 GLOBAL CGMS MARKET SHARE BY DEMOGRAPHICS 2018 & 2027 (%)
• FIGURE 10 GLOBAL CGMS MARKET BY ADULT POPULATION (>14YEARS) 2019-2027 ($ MILLION)
• FIGURE 11 GLOBAL CGMS MARKET BY CHILD POPULATION (≤14YEARS) 2019-2027 ($ MILLION)
• FIGURE 12 GLOBAL SMBG MARKET SHARE BY COMPONENT TYPE 2018 & 2027 (%)
• FIGURE 13 GLOBAL SMBG MARKET BY TEST STRIPS 2019-2027 ($ MILLION)
• FIGURE 14 GLOBAL SMBG TEST STRIPS MARKET BY REGION 2019-2027 ($ MILLION)
• FIGURE 15 GLOBAL SMBG MARKET BY GLUCOSE METER 2019-2027 ($ MILLION)
• FIGURE 16 GLOBAL SMBG GLUCOSE METER MARKET BY REGION 2019-2027 ($ MILLION)
• FIGURE 17 GLOBAL SMBG LANCETS MARKET 2019-2027 ($ MILLION)
• FIGURE 18 GLOBAL SMBG MARKET SHARE BY END-USER 2018 & 2027 (%)
• FIGURE 19 GLOBAL SMBG MARKET BY HOME SETTING 2019-2027 ($ MILLION)
• FIGURE 20 GLOBAL SMBG MARKET BY CLINICAL 2019-2027 ($ MILLION)
• FIGURE 21 GLOBAL SMBG MARKET BY HOSPITAL 2019-2027 ($ MILLION)
• FIGURE 22 GLOBAL SMBG MARKET SHARE BY APPLICATION 2018 & 2027 (%)
• FIGURE 23 GLOBAL SMBG MARKET BY TYPE 1 DIABETES 2019-2027 ($ MILLION)
• FIGURE 24 GLOBAL SMBG MARKET BY TYPE 2 DIABETES 2019-2027 ($ MILLION)
• FIGURE 25 GLOBAL SMBG MARKET BY GESTATIONAL DIABETES 2019-2027 ($ MILLION)
• FIGURE 26 PORTER'S FIVE FORCE MODEL
• FIGURE 27 VALUE CHAIN OF GLOBAL CGMS MARKET
• FIGURE 28 GLOBAL GGMS MARKET SHARE BY REGION 2018 & 2027 (%)
• FIGURE 29 THE UNITED STATES CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 30 THE UNITED STATES SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 31 CANADA CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 32 CANADA SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 33 EUROPE CGMS MARKET SHARE BY COUNTRY 2018 & 2027 (%)
• FIGURE 34 THE UNITED KINGDOM CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 35 THE UNITED KINGDOM SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 36 FRANCE CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 37 FRANCE SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 38 GERMANY CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 39 GERMANY SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 40 ITALY CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 41 ITALY SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 42 SPAIN CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 43 SPAIN SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 44 RUSSIA CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 45 RUSSIA SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 46 REST OF EUROPE (ROE) CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 47 REST OF EUROPE (ROE) SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 48 ASIA-PACIFIC CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 49 CHINA CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 50 CHINA SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 51 INDIA CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 52 INDIA SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 53 AUSTRALIA CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 54 AUSTRALIA SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 55 JAPAN CGMS MARKET REVENUE 2019-2027 ($ MILLION)
• FIGURE 56 JAPAN SMBG MARKET REVENUE, 2019-2027 ($ MILLION)
• FIGURE 57 SOUTH KOREA CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 58 SOUTH KOREA SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 59 INDONESIA CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 60 INDONESIA SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 61 MALAYSIA CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 62 MALAYSIA SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 63 PHILIPPINES CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 64 PHILIPPINES SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 65 THAILAND CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 66 THAILAND SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 67 VIETNAM CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 68 VIETNAM SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 69 REST OF ASIA-PACIFIC CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 70 REST OF ASIA-PACIFIC SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 71 LATIN AMERICA CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 72 LATIN AMERICA SMBG MARKET 2019-2027 ($ MILLION)
• FIGURE 73 MIDDLE EAST AND AFRICA CGMS MARKET 2019-2027 ($ MILLION)
• FIGURE 74 MIDDLE EAST AND AFRICA SMBG MARKET 2019-2027 ($ MILLION)

KEY FINDINGS

Continuous Glucose monitoring system (CGM) device is a system used for measuring glucose levels in the interstitial fluid present between the cells of the skin and displaying it on monitor whereas self-monitoring of blood glucose (SMBG) refers to the monitoring of glucose level personally using SMBG devices available. The CGMS market is anticipated to grow to $15,244.7 million by 2027, at a CAGR of 32.12% between 2019 and 2027 whereas the SMBG market is anticipated to grow to $22262.6 million by 2027 at a CAGR of 5.23% between 2019 and 2027.

MARKET INSIGHTS

The global SMBG devices market is organized and is expected to grow rapidly with the increase in the incidence of diabetics across the globe. Vendors are offering SMBG devices that are safe, portable, accurate, and require low power consumption. The availability of innovative and advanced SMBG devices will propel sales of these devices and spur market growth.

It faces stringent regulations and approval issues from government authorities, especially the US FDA, whose very strict restrictions tightly regulates the glucose monitoring system market. Many diabetologists are unwilling to use CGM in their practices as taking the precaution of patients using this technology is rather time-consuming.

REGIONAL INSIGHTS

The regional segmentation of the markets is carried out in North America, Europe, Asia Pacific, and the Rest of World. The North American market is expected to capture the highest revenue share by 2027, for both CGMS and SMBG markets, driven by high awareness related to diabetes. Asia-Pacific is predicted to grow more significantly over the forecast period, owing to the ever-increasing unaddressed diabetic patient pool in these regions.

COMPETITIVE INSIGHTS

GlySens Inc., Abbott, Ypsomed, Medtronic, Apex Biotechnology Corp., Wockhardt, Becton Dickinson And Company, B Braun Melsungen AG, Nemaura Medical Inc., Senseonics Inc., Morepen Laboratories Ltd., Roche Diagnostics, Johnson and Johnson, ARKRAY Inc., Tandem Diabetes Care, Terumo, Insulet Corp., Ascensia, I-Sens Inc., and Dexcom are some of the noted market players in the global glucose monitoring systems market.

Table of Contents

1. RESEARCH SCOPE

• 1.1. STUDY GOALS
• 1.2. SCOPE OF THE STUDY MARKET
• 1.3. WHO WILL FIND THIS REPORT USEFUL?
• 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

• 2.1. SOURCES OF DATA
• 2.2. BOTTOM-UP APPROACH
• 2.3. TOP-DOWN APPROACH
• 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

• 3.1. MARKET SUMMARY
• 3.2. KEY FINDINGS
• 3.2.1. CGMS MARKET IS ANTICIPATED TO BE THE FASTEST GROWING MARKET
• 3.2.2. SELF-MONITORING OF BLOOD GLUCOSE HAS HUGE MARKET OPPORTUNITY
• 3.2.3. COLLABORATION OF SIGNIFICANT COMPANIES TO DEVELOP INTEGRATED CGMS-ENABLED INSULIN PUMPS

4. MARKET DYNAMICS

• 4.1. MARKET SCOPE & DEFINITION
• 4.2. MARKET DRIVERS
• 4.2.1. RISE IN THE INCIDENCE OF DIABETES
• 4.2.2. INCREASE IN HEALTHCARE EXPENDITURE
• 4.2.3. INCREASING FOCUS ON RESEARCH AND DEVELOPMENT
• 4.2.4. TECHNOLOGY INTEGRATION
• 4.2.5. INCREASING CGMS AND SMBG AFFORDABILITY
• 4.2.6. TECHNOLOGICAL ADVANCES IN GMS DEVICES
• 4.2.7. AWARENESS AMONG THE GENERAL POPULATION
• 4.3. MARKET RESTRAINTS
• 4.3.1. HINDERANCE FROM GOVERNMENT REGULATIONS
• 4.3.2. INADEQUATE REIMBURSEMENT OPTIONS FOR CONTINUOUS GLUCOSE MONITORING DEVICES
• 4.3.3. LACK OF AWARENESS OF THE DIAGNOSTIC OPPORTUNITIES
• 4.4. MARKET OPPORTUNITIES
• 4.4.1. RISING AWARENESS CAMPAIGNS ON DIABETES
• 4.4.2. RISE IN EMERGING TECHNOLOGIES
• 4.5. MARKET CHALLENGES
• 4.5.1. INTENSE COMPETITION AMONG VENDORS
• 4.5.2. INACCURACY IN READING OF GMS DEVICES
• 4.5.3. INCREASINGLY STRINGENT GOVERNMENT REGULATIONS

5. CGMS MARKET BY COMPONENT TYPE

• 5.1. SENSORS
• 5.2. TRANSMITTERS AND RECEIVERS
• 5.3. INSULIN PUMP

6. CGMS MARKET BY END-USERS

• 6.1. HOME SETTINGS
• 6.2. DIAGNOSTICS AND CLINICS
• 6.3. HOSPITALS

7. CGMS MARKET BY DEMOGRAPHICS

• 7.1. ADULT POPULATION (>14YEARS)
• 7.2. CHILD POPULATION (≤14YEARS)

8. SMBG MARKET OVERVIEW

9. SMBG MARKET BY COMPONENT TYPE

• 9.1. TEST STRIPS
• 9.2. GLUCOSE METER
• 9.3. LANCETS

10. SMBG MARKET BY END-USER

• 10.1. HOME SETTINGS
• 10.2. CLINICAL
• 10.3. HOSPITAL

11. SMBG MARKET BY APPLICATION

• 11.1. TYPE 1 DIABETES
• 11.2. TYPE 2 DIABETES
• 11.3. GESTATIONAL DIABETES

12. KEY ANALYTICS

• 12.1. PORTER'S 5 FORCE ANALYSIS
• 12.1.1. THREAT OF NEW ENTRANT
• 12.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
• 12.1.3. BARGAINING POWER OF BUYERS
• 12.1.4. BARGAINING POWER OF SUPPLIER
• 12.1.5. INTENSITY OF COMPETITIVE RIVALRY
• 12.2. KEY BUYING CRITERIA
• 12.3. KEY TRENDS
• 12.3.1. DEVELOPMENT OF HIGH-QUALITY WEARABLE DEVICES
• 12.3.2. MOBILE HEALTHCARE MAKING THE DEVICES MORE USER-FRIENDLY
• 12.3.3. INCREASING EFFORTS TOWARDS SPREAD OF AWARENESS
• 12.3.4. INCREASE IN NON-INVASIVE DEVICES
• 12.3.5. ENERGY HARVESTING TECHNOLOGY FOR UNINTERRUPTED USAGE
• 12.4. REGULATION OF BLOOD SUGAR
• 12.5. VALUE CHAIN ANALYSIS
• 12.6. OPPORTUNITY MATRIX

13. REGIONAL ANALYSIS

• 13.1. NORTH AMERICA
• 13.1.1. THE UNITED STATES
• 13.1.1.1. THE UNITED STATES HEALTH AND HEALTHCARE
• 13.1.1.2. THE UNITED STATES PHARMACEUTICAL MARKET
• 13.1.2. CANADA
• 13.1.2.1. CANADA HEALTH AND HEALTHCARE
• 13.1.2.2. CANADA PHARMACEUTICAL MARKET
• 13.1.2.3. CANADA DIABETES MARKET
• 13.2. EUROPE
• 13.2.1. THE UNITED KINGDOM
• 13.2.1.1. THE UNITED KINGDOM HEALTH AND HEALTHCARE
• 13.2.1.2. THE UNITED KINGDOM HEALTHCARE PROVISION
• 13.2.1.3. THE UNITED KINGDOM PRIVATE SECTOR INVOLVEMENT
• 13.2.1.4. THE UNITED KINGDOM PHARMACEUTICALS
• 13.2.2. FRANCE
• 13.2.2.1. FRANCE HEALTH AND HEALTHCARE
• 13.2.2.2. FRANCE HEALTHCARE PROVISION
• 13.2.3. GERMANY
• 13.2.3.1. GERMANY HEALTH AND HEALTHCARE
• 13.2.3.2. GERMANY PHARMACEUTICAL MARKET
• 13.2.4. ITALY
• 13.2.4.1. ITALY HEALTH AND HEALTHCARE
• 13.2.4.2. ITALY HEALTHCARE PROVISION
• 13.2.4.3. ITALY PHARMACEUTICAL MARKET
• 13.2.5. SPAIN
• 13.2.5.1. SPAIN HEALTH AND HEALTHCARE
• 13.2.5.2. SPAIN HEALTHCARE PROVISION
• 13.2.5.3. SPAIN PHARMACEUTICAL SERVICES
• 13.2.6. RUSSIA
• 13.2.6.1. RUSSIA HEALTH AND HEALTHCARE
• 13.2.6.2. RUSSIA PHARMACEUTICAL SERVICES
• 13.2.7. REST OF EUROPE (ROE)
• 13.3. ASIA-PACIFIC (APAC)
• 13.3.1. CHINA
• 13.3.1.1. CHINA HEALTH AND HEALTHCARE
• 13.3.1.2. CHINA PHARMACEUTICAL MARKET
• 13.3.1.3. CHINA DIABETES MARKET
• 13.3.1.4. MARKET TRENDS
• 13.3.2. INDIA
• 13.3.2.1. INDIA HEALTH AND HEALTHCARE
• 13.3.2.2. INDIA REGULATORY CHANGES
• 13.3.2.3. INDIA PHARMACEUTICAL MARKET
• 13.3.2.4. INDIA DIABETES MARKET
• 13.3.3. AUSTRALIA
• 13.3.3.1. MARKET TRENDS
• 13.3.4. JAPAN
• 13.3.4.1. JAPAN HEALTH AND HEALTHCARE
• 13.3.4.2. JAPAN PHARMACEUTICAL MARKET
• 13.3.4.3. JAPAN DIABETES MARKET
• 13.3.4.4. MARKET TRENDS
• 13.3.5. SOUTH KOREA
• 13.3.5.1. MARKET TRENDS
• 13.3.6. INDONESIA
• 13.3.6.1. MARKET TRENDS
• 13.3.7. MALAYSIA
• 13.3.7.1. MARKET TRENDS
• 13.3.8. PHILIPPINES
• 13.3.8.1. MARKET TRENDS
• 13.3.9. THAILAND
• 13.3.9.1. MARKET TRENDS
• 13.3.10. VIETNAM
• 13.3.10.1. MARKET TRENDS
• 13.3.11. REST OF ASIA-PACIFIC (ROAP)
• 13.4. REST OF WORLD
• 13.4.1. LATIN AMERICA
• 13.4.1.1. BRAZIL HEALTH AND HEALTHCARE
• 13.4.1.2. BRAZIL PHARMACEUTICAL MARKET
• 13.4.1.3. MEXICO HEALTH AND HEALTHCARE
• 13.4.1.4. MEXICO PHARMACEUTICAL MARKET
• 13.4.2. MIDDLE EAST AND AFRICA (MEA)

14. COMPETITIVE LANDSCAPE

• 14.1. MARKET POSITION ANALYSIS
• 14.2. COMPANY PROFILES
• 14.2.1. ABBOTT
• 14.2.2. APEX BIOTECHNOLOGY CORP.
• 14.2.3. ARKRAY INC.
• 14.2.4. ASCENSIA
• 14.2.5. B BRAUN MELSUNGEN AG
• 14.2.6. BECTON DICKINSON AND COMPANY
• 14.2.7. DEXCOM
• 14.2.8. GLYSENS INC.
• 14.2.9. INSULET CORP.
• 14.2.10. I-SENS INC.
• 14.2.11. JOHNSON AND JOHNSON
• 14.2.12. MEDTRONIC
• 14.2.13. MOREPEN LABORATORIES LTD.
• 14.2.14. NEMAURA MEDICAL INC.
• 14.2.15. ROCHE DIAGNOSTICS
• 14.2.16. SENSEONICS INC.
• 14.2.17. TANDEM DIABETES CARE
• 14.2.18. TERUMO
• 14.2.19. WOCKHARDT
• 14.2.20. YPSOMED